{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:06:58Z","timestamp":1790698018519,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T00:00:00Z","timestamp":1438300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s00259-015-3125-3","type":"journal-article","created":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T01:03:53Z","timestamp":1438218233000},"page":"1976-1983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":185,"title":["Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer"],"prefix":"10.1007","volume":"42","author":[{"given":"Levent","family":"Kabasakal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"AbuQbeitah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslan","family":"Ayg\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Yeyin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meltem","family":"Ocak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turkay","family":"Toklu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,31]]},"reference":[{"key":"3125_CR1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","volume":"1","author":"GL Wright","year":"1995","unstructured":"Wright GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995;1:18\u201328.","journal-title":"Urol Oncol"},{"key":"3125_CR2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.humpath.2006.11.012","volume":"38","author":"S Perner","year":"2007","unstructured":"Perner S, Hofer MD, Kim R, Shah RB, Li H, M\u00f6ller P, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007;38:696\u2013701.","journal-title":"Hum Pathol"},{"key":"3125_CR3","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81\u20135.","journal-title":"Clin Cancer Res"},{"key":"3125_CR4","doi-asserted-by":"crossref","unstructured":"Eder M, Sch\u00e4fer M, Bauder-W\u00fcst U, Hull W-E, W\u00e4ngler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012;23:688\u201397.","DOI":"10.1021\/bc200279b"},{"key":"3125_CR5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/pros.22784","volume":"74","author":"M Eder","year":"2014","unstructured":"Eder M, Sch\u00e4fer M, Bauder-W\u00fcst U, Haberkorn U, Eisenhut M, Kopka K. Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate 2014;74:659\u201368.","journal-title":"Prostate"},{"key":"3125_CR6","doi-asserted-by":"crossref","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013;40:486\u201395.","DOI":"10.1007\/s00259-012-2298-2"},{"key":"3125_CR7","doi-asserted-by":"crossref","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:197\u2013209.","DOI":"10.1007\/s00259-014-2949-6"},{"key":"3125_CR8","doi-asserted-by":"crossref","unstructured":"Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, et al. Evaluation of PSMA PET\/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun 2015;36:582\u20137.","DOI":"10.1097\/MNM.0000000000000290"},{"key":"3125_CR9","doi-asserted-by":"crossref","unstructured":"Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Bene\u0161ov\u00e1 M, Mier W, et al. [(177)Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:987\u20138.","DOI":"10.1007\/s00259-014-2978-1"},{"key":"3125_CR10","doi-asserted-by":"crossref","unstructured":"Bene\u0161ov\u00e1 M, Sch\u00e4fer M, Bauder-W\u00fcst U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 2015;56:914\u201320.","DOI":"10.2967\/jnumed.114.147413"},{"key":"3125_CR11","first-page":"37S","volume":"40","author":"JA Siegel","year":"1999","unstructured":"Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S\u201361S.","journal-title":"J Nucl Med"},{"key":"3125_CR12","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.apradiso.2008.01.002","volume":"66","author":"S Brown","year":"2008","unstructured":"Brown S, Bailey DL, Willowson K, Baldock C. Investigation of the relationship between linear attenuation coefficients and CT Hounsfield units using radionuclides for SPECT. Appl Radiat Isot 2008;66:1206\u201312.","journal-title":"Appl Radiat Isot"},{"key":"3125_CR13","unstructured":"Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, et al. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med 2004;45:1725\u201333."},{"key":"3125_CR14","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.mnm.0000167910.76718.ad","volume":"26","author":"HM Thierens","year":"2005","unstructured":"Thierens HM, Monsieurs MA, Bacher K. Patient dosimetry in radionuclide therapy: the whys and the wherefores. Nucl Med Commun 2005;26:593\u20139.","journal-title":"Nucl Med Commun"},{"key":"3125_CR15","doi-asserted-by":"crossref","unstructured":"Glatting G, Bardi\u00e8s M, Lassmann M. Treatment planning in molecular radiotherapy. Z Med Phys 2013;23:262\u20139.","DOI":"10.1016\/j.zemedi.2013.03.005"},{"key":"3125_CR16","doi-asserted-by":"crossref","unstructured":"Wehrmann C, Senftleben S, Zachert C, M\u00fcller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 2007;22:406\u201316.","DOI":"10.1089\/cbr.2006.325"},{"key":"3125_CR17","doi-asserted-by":"crossref","unstructured":"Kwekkeboom D, Bakker W, Kooij P, Konijnenberg M, Srinivasan A, Erion J, et al. [177 Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001;28:1319\u201325.","DOI":"10.1007\/s002590100574"},{"key":"3125_CR18","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1007\/s00259-009-1072-6","volume":"36","author":"F Forrer","year":"2009","unstructured":"Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 2009;36:1138\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3125_CR19","doi-asserted-by":"crossref","unstructured":"Svensson J, Berg G, W\u00e4ngberg B, Larsson M, Forssell-Aronsson E, Bernhardt P. Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment. Eur J Nucl Med Mol Imaging 2015;42:947\u201355..","DOI":"10.1007\/s00259-015-3001-1"},{"key":"3125_CR20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00259-009-1216-8","volume":"37","author":"M Sandstr\u00f6m","year":"2010","unstructured":"Sandstr\u00f6m M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe(1)-Tyr(3)-octreotate. Eur J Nucl Med Mol Imaging 2010;37:212\u201325.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3125_CR21","doi-asserted-by":"crossref","unstructured":"Van Essen M, Krenning EP, Kam BLR, de Jong M, Valkema R, Kwekkeboom DJ. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 2009;5:382\u201393.","DOI":"10.1038\/nrendo.2009.105"},{"key":"3125_CR22","doi-asserted-by":"crossref","unstructured":"Sandstr\u00f6m M, Garske-Rom\u00e1n U, Granberg D, Johansson S, Widstr\u00f6m C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med 2013;54:33\u201341.","DOI":"10.2967\/jnumed.112.107524"},{"key":"3125_CR23","doi-asserted-by":"crossref","unstructured":"Lassmann M, Chiesa C, Flux G, Bardi\u00e8s M, EANM Dosimetry Committee. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging 2011;38:192\u2013200.","DOI":"10.1007\/s00259-010-1549-3"},{"key":"3125_CR24","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.ijrobp.2009.06.090","volume":"76","author":"JO Deasy","year":"2010","unstructured":"Deasy JO, Moiseenko V, Marks L, Chao KSC, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys 2010;76:S58\u201363.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3125_CR25","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1177\/0022034509343143","volume":"88","author":"O Grundmann","year":"2009","unstructured":"Grundmann O, Mitchell GC, Limesand KH. Sensitivity of salivary glands to radiation: from animal models to therapies. J Dent Res 2009;88:894\u2013903.","journal-title":"J Dent Res"},{"key":"3125_CR26","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ijrobp.2006.09.021","volume":"67","author":"Y Li","year":"2007","unstructured":"Li Y, Taylor JMG, Ten Haken RK, Eisbruch A. The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 2007;67:660\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3125_CR27","doi-asserted-by":"crossref","unstructured":"Jeong SY, Kim HW, Lee S-W, Ahn B-C, Lee J. Salivary gland function 5\u00a0years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms. Thyroid 2013;23:609\u201316.","DOI":"10.1089\/thy.2012.0106"},{"key":"3125_CR28","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2967\/jnumed.108.061382","volume":"50","author":"RK Grewal","year":"2009","unstructured":"Grewal RK, Larson SM, Pentlow CE, Pentlow KS, Gonen M, Qualey R, et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med 2009;50:1605\u201310.","journal-title":"J Nucl Med"},{"key":"3125_CR29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0030-4220(89)90140-0","volume":"68","author":"LM Sreebny","year":"1989","unstructured":"Sreebny LM, Valdini A, Yu A. Xerostomia. Part II: relationship to nonoral symptoms, drugs, and diseases. Oral Surg Oral Med Oral Pathol 1989;68:419\u201327.","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"3125_CR30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/108497803321269403","volume":"18","author":"K Norrgren","year":"2003","unstructured":"Norrgren K, Svegborn SL, Areberg J, Mattsson S. Accuracy of the quantification of organ activity from planar gamma camera images. Cancer Biother Radiopharm 2003;18:125\u201331.","journal-title":"Cancer Biother Radiopharm"},{"key":"3125_CR31","doi-asserted-by":"crossref","unstructured":"Garkavij M, Nickel M, Sj\u00f6green-Gleisner K, Ljungberg M, Ohlsson T, Wing\u00e5rdh K, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer 2010;116:1084\u201392.","DOI":"10.1002\/cncr.24796"},{"key":"3125_CR32","doi-asserted-by":"crossref","unstructured":"Kletting P, M\u00fcller B, Erentok B, Schmaljohann J, Behrendt FF, Reske SN, et al. Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. Med Phys 2012;39:5708\u201317.","DOI":"10.1118\/1.4747266"},{"key":"3125_CR33","doi-asserted-by":"crossref","unstructured":"Hindorf C, Glatting G, Chiesa C, Lind\u00e9n O, Flux G, EANM Dosimetry Committee. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging 2010;37:1238\u201350.","DOI":"10.1007\/s00259-010-1422-4"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-015-3125-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-015-3125-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-015-3125-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:06:26Z","timestamp":1558699586000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-015-3125-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,31]]},"references-count":33,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["3125"],"URL":"https:\/\/doi.org\/10.1007\/s00259-015-3125-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,31]]}}}